S-1/A: Estrella Immunopharma Amends S-1, Details Clinical Progress & Funding Needs

Estrella Immunopharma, a clinical-stage biopharmaceutical company, filed an S-1/A to register shares for resale, highlighting ongoing clinical trial progress for EB103 and recent capital raises amidst significant operating losses and going concern doubts.

Summary

• Estrella Immunopharma is a clinical-stage biopharmaceutical company focused on T-cell therapies for cancers and autoimmune diseases, leveraging its ARTEMIS T-Cell Receptor Platform.
• The lead product candidate, EB103, is a CD19-directed ARTEMIS T-cell therapy in a Phase I/II clinical trial (STARLIGHT-1) for relapsed or refractory B-cell Non-Hodgkin's Lymphomas.
• As of September 2025, nine patients have been treated in the STARLIGHT-1 trial, with the high-dose cohort achieving a 100% complete response rate at Month 1 in all evaluable patients, and no treatment-related serious adverse events reported in Phase I.
• The independent Data Safety Monitoring Board (DSMB) recommended advancing the STARLIGHT-1 trial into the Phase II expansion phase.
• The company is also developing EB104, a dual-targeting T-cell therapy for CD19 and CD22, and exploring EB103's use with Imugene's CF33-CD19t oncolytic virus for solid tumors.
• Estrella reported net losses of approximately $4.8 million for the three months ended September 30, 2025, and $12.5 million for the nine months ended September 30, 2025.
• The accumulated deficit as of September 30, 2025, was approximately $36.4 million.
• Cash and cash equivalents stood at approximately $1.6 million as of September 30, 2025.
• The company raised approximately $2.4 million in gross proceeds from private placements between May and September 2025, and an additional $8.0 million in gross proceeds from a registered direct offering and private placement of warrants on January 6, 2026.
• Estrella is a controlled company, with Eureka Therapeutics, Inc. holding approximately 60.1% of outstanding Common Stock and voting power as of January 11, 2026.
• The company has a history of operating losses and expects to incur significant losses for the foreseeable future, requiring substantial additional funding to finance operations.

Sentiment

Score: 3

Explanation: The company faces severe financial challenges, including recurring losses, a significant accumulated deficit, and a going concern warning from auditors. While early clinical trial data for EB103 is promising, the financial instability and continuous need for capital raises, coupled with Nasdaq compliance issues, present substantial risks that outweigh the clinical positives for an investor.

Positives

• EB103's Phase I dose-escalation in the STARLIGHT-1 clinical trial showed a favorable safety profile with no treatment-related serious adverse events.
• The high-dose cohort of EB103 achieved a 100% complete response rate at Month 1 in all evaluable patients, including high-risk individuals ineligible for commercial CD19 products.
• An independent Data Safety Monitoring Board (DSMB) recommended advancing the STARLIGHT-1 trial into the Phase II expansion phase.
• Successfully completed a registered direct offering and private placement of warrants on January 6, 2026, generating approximately $8.0 million in gross proceeds.
• Activated a second clinical trial site for STARLIGHT-1 as of June 30, 2025.

Negatives

• The company has a history of significant operating losses, with a net loss of approximately $4.8 million for the three months ended September 30, 2025, and $12.5 million for the nine months ended September 30, 2025.
• An accumulated deficit of approximately $36.4 million as of September 30, 2025, indicates substantial past losses.
• Cash and cash equivalents were approximately $1.6 million as of September 30, 2025, which is a low liquidity position given ongoing R&D expenses.
• The independent registered public accounting firm included an explanatory paragraph in its report expressing substantial doubt about the company's ability to continue as a going concern.
• The company received a notice from Nasdaq on January 7, 2026, for non-compliance with Rule 5620(a) for not holding an annual meeting of shareholders within twelve months of the fiscal year end.
• The closing price of common stock was $1.20 per share on January 9, 2026, significantly lower than the $11.50 exercise price of public warrants, making warrant exercise unlikely as a liquidity source.
• The company's management team has limited experience in managing day-to-day operations of a public company, potentially leading to increased costs and compliance challenges.
• Identified material weaknesses in internal control over financial reporting due to a lack of qualified full-time personnel with appropriate accounting knowledge and experience.

Risks

• History of significant operating losses and expectation of continued losses, with no guarantee of achieving or maintaining profitability.
• Ability to continue as a going concern is dependent on obtaining sufficient additional funding, which may not be available on acceptable terms or at all.
• Product candidates are in early stages of development, and clinical development is lengthy, expensive, and has an uncertain outcome.
• Substantial dependence on Eureka Therapeutics, Inc. for intellectual property, clinical trials, and manufacturing of product candidates.
• Inability to obtain and maintain intellectual property protection for technology and products could harm commercialization efforts.
• Failure to obtain U.S. or foreign regulatory approval would prevent commercialization of product candidates.
• Clinical trials may fail, suffer delays, or encounter serious complications or side effects, leading to discontinuation or denial of approval.
• Inability to successfully use and expand the ARTEMIS platform to develop new product candidates or identify viable new therapeutic opportunities.
• Interim, topline, and preliminary clinical data may change as more patient data become available or additional analyses are conducted, potentially differing from final results.
• Failure to achieve projected discovery and development milestones and other anticipated key events in announced timeframes.
• Difficulties enrolling patients in clinical trials could delay or adversely affect clinical development activities.
• Manufacturing of product candidates is complex, and reliance on Eureka as a sole supplier poses risks of production difficulties or disruptions.
• Market opportunities for product candidates may be smaller than anticipated, adversely affecting future product revenues.
• Management has a limited understanding of Artificial Intelligence (AI), potentially hindering risk assessment or benefit capture, and exposing the company to competitive or security risks.
• Intense competition from larger, better-funded pharmaceutical and biotechnology companies developing similar or superior therapies.
• Inability to attract and retain qualified key management, technical personnel, and employees.
• Difficulties in managing growth and expanding operations, leading to significant costs and diversion of management resources.
• Inability to develop internal sales, marketing, and distribution capabilities or enter into acceptable third-party arrangements for commercialization.
• Negative public opinion and scrutiny of immunotherapy approaches could impact public perception, regulatory actions, and demand for products.
• Potential future international operations expose the company to business, political, operational, and financial risks.
• Significant product liability risk, with potential for claims, regulatory investigations, recalls, and financial harm.
• Risk of fraud or other misconduct by employees, principal investigators, consultants, and commercial collaborators.
• Dependence on sophisticated information technology systems and data processing, with risks of security or data privacy breaches.
• Failure to comply with laws regulating environmental protection and health and human safety.
• Adverse effects from military actions (Ukraine, Israel-Hamas) on capital markets, liquidity, and ability to raise capital.
• Volatility in capital markets and lower market prices for securities may affect ability to access new capital.
• Inflation and higher interest rates could increase operating costs and adversely affect liquidity and capital raising ability.
• Incurrence of incremental costs as a standalone public company, and potential inability to replace services from Eureka on comparable terms.
• Potential conflicts of interest for officers and directors due to their equity interests in or positions with Eureka Therapeutics, Inc.
• Inability to obtain or protect intellectual property rights, or challenges to existing rights, could harm competitive position.
• Patent terms may not adequately protect competitive position for a sufficient period.
• Changes in U.S. patent law or foreign patent law could diminish the value of patents.
• Lawsuits or litigation to protect or enforce intellectual property rights could result in substantial costs and liability.
• Inability to acquire or in-license relevant third-party intellectual property rights on acceptable terms.
• Failure to comply with obligations under license, collaboration, or other intellectual property-related agreements could lead to loss of rights or damages.
• Negative data from licensed technology in third-party territories could adversely affect development in other territories.
• Ongoing regulatory obligations and continued regulatory review, even if product candidates are approved, may result in significant additional expense or market withdrawal.
• Unfavorable pricing regulations or third-party coverage and reimbursement policies could harm commercial viability.
• Non-compliance with U.S. and foreign anti-corruption and anti-money laundering laws could lead to criminal or civil liability.
• Disruptions at the FDA and other government agencies due to staffing, funding shortages, or shutdowns could hinder regulatory review.
• Adverse effects from natural disasters on business continuity and disaster recovery plans.
• Quarterly operating results may fluctuate significantly or fall below expectations, causing stock price volatility.
• Claims that employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties.
• Management team not subject to non-competition restrictions if they terminate employment, potentially diminishing strategic advantages.
• Common Stock price volatility due to various factors, including clinical trial results, regulatory developments, and market conditions.
• Failure to maintain compliance with Nasdaq listing standards could lead to delisting and additional trading restrictions.
• Significant costs from class action litigation due especially to stock volatility in the biopharmaceutical industry.
• As a controlled company, reliance on exemptions from certain corporate governance requirements could reduce shareholder protections.

Future Outlook

The company expects its net losses and research and development expenses to increase substantially as it continues the EB103 clinical trial, develops preclinical programs, seeks regulatory approval, scales clinical and regulatory capabilities, expands its intellectual property portfolio, and incurs additional costs associated with operating as a public company. Future capital requirements are significant and uncertain, dependent on successful product development, regulatory approvals, and market acceptance. The company intends to raise additional capital through equity or debt financings, collaborations, and licensing arrangements, but cannot guarantee availability on favorable terms.

Management Comments

• Management believes existing cash and cash equivalents, combined with the ability to raise funds through the Equity Line Shares, will be sufficient to fund operations for at least the next 12 months from the filing date.
• Management acknowledges that the estimate of sufficient funds is based on assumptions that may prove wrong, and available capital could be consumed sooner than expected.

Industry Context

Estrella Immunopharma operates in the highly competitive clinical-stage biopharmaceutical sector, specifically focusing on T-cell therapies, which aim to overcome limitations of traditional CAR-T therapies like high toxicity and prohibitive costs. The company's 'mark and kill' strategy for solid tumors, in collaboration with Imugene, addresses a major barrier in T-cell therapy for solid cancers by inducing CD19 expression on tumor cells. The industry faces significant challenges in funding capital-intensive development, navigating complex regulatory pathways, and competing with numerous established and emerging players.

Management Changes

Corporate Governance

Legal Proceedings

• The company is subject to loss contingencies, such as legal proceedings and claims arising out of its business, including government investigations and tax matters.
• Amounts accrued for such matters are not deemed material to the unaudited condensed consolidated financial statements.
• The company may be required to indemnify its licensors for costs associated with adversarial proceedings or litigation related to intellectual property rights.
• Third parties may assert infringement claims against the company, its licensors, or strategic collaborators based on existing or future patents.

Related Party Transactions

• **License Agreement with Eureka Therapeutics, Inc. (June 28, 2022):** Grants Estrella an exclusive license for ARTEMIS T-cell technology targeting CD19 and CD22. Estrella was obligated to pay a $1.0 million upfront fee (fully paid as of Sep 30, 2025), development milestone payments (two milestones of $50,000 each paid for IND submission and first patient dosed), and single-digit royalty payments on net sales. Eureka is solely responsible for manufacturing and supplying clinical quantities of licensed products.
• **Services Agreement with Eureka Therapeutics, Inc. (June 28, 2022):** Eureka provides technology transfer and technical assistance services. Estrella agreed to pay $10.0 million in 12 equal monthly installments (all settled as of Sep 30, 2025) and reimburse pass-through costs. No pass-through costs incurred for the three and nine months ended Sep 30, 2025.
• **Statement of Work (SOW) with Eureka Therapeutics, Inc. (March 4, 2024, amended May 13, 2024):** Relates to clinical trial services for the STARLIGHT-1 trial. Estrella agreed to pay Eureka total fees of $33.0 million for all milestones (assuming 20 patients and one site), plus an additional $500,000 if a second site is activated. As of Sep 30, 2025, Estrella paid $3.5 million for achieved milestones and deposited $1.5 million for patient treatment expenses. Accrued approximately $12.9 million in related-party liabilities for dosing and site activation milestones.
• **Series AA Preferred Stock (June 28, 2022):** Eureka contributed assets to Estrella in exchange for 105,000,000 shares of Estrella's Series AA Preferred Stock. As of Sep 30, 2025, Eureka owned approximately 66.93% of the company on a fully diluted basis.
• **Office Sublease Agreements with Eureka Therapeutics, Inc.:** Estrella leases office space from Eureka. Monthly rent payments of $2,000 were incurred for various periods, including for the nine months ended Sep 30, 2025. As of Sep 30, 2025, an outstanding balance of $4,000 for lease payments was recorded as accounts payable to a related party.
• **Consulting Agreement with CoFame Investment Holding LLC (November 1, 2024):** CoFame, managed by Hong Zhang (a director of Estrella), provides advisory and consulting services in Asia. Estrella accrued $18,333 in unpaid consulting fees as of Sep 30, 2025, and recorded $164,996 in consulting expense for the nine months ended Sep 30, 2025.

Stakeholder Impact

• **Shareholders:** Dilution risk from future equity offerings and warrant exercises. Potential for significant downward pressure on stock price due to resale of a substantial number of shares (22.0% of outstanding shares registered for resale). The 'going concern' uncertainty poses a fundamental risk to investment value. Existing stockholders' ownership interest will decrease with future capital raises.
• **Employees:** Continued employment and potential for equity awards under the 2023 Omnibus Incentive Plan, but also subject to the company's financial stability and ability to continue operations. Management team has limited public company experience, potentially impacting operational efficiency.
• **Customers/Patients:** Potential for new T-cell therapies (EB103, EB104) to address unmet medical needs in B-cell malignancies and solid tumors, offering safer and more efficacious options. However, clinical trial delays or failures could impact availability of these treatments.
• **Suppliers/Creditors:** Eureka Therapeutics, Inc. is a major related-party supplier and creditor, with significant accrued liabilities and ongoing service agreements. The company's ability to meet these obligations depends on its financial health and capital raising efforts. Other third-party suppliers face similar payment risks due to the company's going concern status.
• **Regulatory Authorities:** Ongoing compliance with FDA and other regulatory requirements is critical for product development and approval. Non-compliance could lead to sanctions, delays, or withdrawal of approvals.

Next Steps

• Continue the Phase I/II STARLIGHT-1 clinical trial for EB103, advancing into the Phase II expansion phase.
• Continue development of preclinical programs.
• Seek regulatory approval for product candidates that successfully complete clinical trials.
• Scale up clinical and regulatory capabilities.
• Adapt regulatory compliance efforts for marketed products.
• Maintain, expand, and protect the intellectual property portfolio.
• Add operational, financial, and management information systems and personnel.
• Incur additional legal, accounting, and other expenses associated with operating as a public company.
• Submit a plan to Nasdaq by February 23, 2026, to regain compliance for the annual meeting requirement.

Key Dates

Recommendation

Estrella Immunopharma is a clinical-stage company with a promising early-stage asset (EB103 showing 100% CR in a small high-dose cohort). However, the company's financial position is extremely precarious, evidenced by recurring significant operating losses, an accumulated deficit of $36.4 million, and a cash balance of only $1.6 million as of September 30, 2025. The independent auditors have issued a 'going concern' warning, indicating substantial doubt about the company's ability to continue operations. While recent capital raises provide some short-term relief, they are dilutive and highlight the continuous need for external funding. The stock price is significantly below warrant exercise prices, suggesting poor market sentiment. For a seasoned investor, the overwhelming financial risks and the fundamental uncertainty of continued operations make this a 'strong sell' despite any early clinical promise, as the probability of financial distress or liquidation is high.

Keywords

T-cell therapy, Biopharmaceutical, Oncology, Autoimmune diseases, ARTEMIS platform, EB103, EB104, Clinical trial, STARLIGHT-1, B-cell Non-Hodgkin's Lymphoma, CD19, CD22, Solid tumors, Immunotherapy, SEC filing, S-1/A, Capital raise, Nasdaq, Going concern, Eureka Therapeutics